shares of hologic inc holx dropped more than 3 in the aftermarket monday after the medical technology company topped wall street estimates for its fiscal third quarter and tweaked its guidance for the fiscal year and for the fiscal fourth quarter hologic lost 405 million or 16 cents a share in the quarter versus earnings of 2284 million or 90 cents a share in the yearago period adjusted for onetime items hologic earned 93 cents a share revenue dropped 2 to 9844 million the company said mostly thanks to lower sales of covid19 assays compared with last year as it had expected analysts polled by factset expected hologic to report adjusted eps of 89 cents a share on sales of 960 million hologic guided for full fiscal 2023 revenue between 3995 billion and 4035 billion from a previous guidance of revenue between 3925 billion and 4025 billion adjusted eps for the year was seen between 387 and 394 the company previously called for adjusted eps between 375 and 395 for the year for the fourth quarter hologic guided for revenue between 910 million and 950 million and adjusted eps of between 80 cents and 87 cents the analysts surveyed by factset expect fourthquarter adjusted earnings of 87 cents on sales of 949 million “hologic again delivered solid diversified growth in our fiscal third quarter excluding the impact of covid” chief executive steve macmillan said in a statement “our results once again highlight that hologic’s transformation and postpandemic performance is durable”